Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
Ferry A.L.M. Eskens(Erasmus MC), U. Bruntsch, G. Greim, Leslie Choi, Ingmar Wolff(Universitätsmedizin Greifswald), R Capdeville, Jaap Verweij(Deutz (Germany)), Denis Lj, André Planting(Erasmus MC Cancer Institute), F.A.J. Muskiet, A.-R. Hanauske(KU Leuven), J Wanders, Nicholas Barbet, C. van Zuylen
PubMed
May 1, 2000
Cited by 25
Related Papers
Cremophor EL
|European Journal of Cancer|2001|1.6k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
|Journal of Clinical Oncology|2020|1.1k
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial
|The Lancet. Gastroenterology & hepatology|2019|597